Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells

References

• Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009;374:324–39
   PubMed Web of Science ®Google Scholar
• Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer 2012;118:878–87
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–60
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Gullà A, Cantafio ME, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242–55
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Rossi M, et al. Genetics and molecular profling of multiple myeloma: novel tools for clinical management? Eur J Cancer 2006;42:1530–8
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Gimsing P, Grønbæk K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol 2013;91:95–105
   PubMed Web of Science ®Google Scholar
• Lionetti M, Agnelli L, Lombardi L, et al. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2009;12:823–37
   Google Scholar
• Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260–70
   PubMed Web of Science ®Google Scholar
• Bakkus M, Dujardin S, Van Riet I, De Waele M. MicroRNA expression analysis in multiple myeloma plasma cells and cell lines by a quantitative real-time PCR approach. Blood 2007;110:729A [Abstract 2472]
   Web of Science ®Google Scholar
• Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885–90
   PubMed Web of Science ®Google Scholar
• Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20–6
   Web of Science ®Google Scholar
• Ameres, SL, Martinez, J, Schroeder, R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 2007;130:101–12
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415–19
   PubMed Web of Science ®Google Scholar
• Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011;43:371–8
   PubMed Web of Science ®Google Scholar
• Tam W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a non-coding RNA. Gene 2001;274:157–67
   PubMed Web of Science ®Google Scholar
• Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005;102:3627–32
   PubMed Web of Science ®Google Scholar
• Saito Y, Suzuki H, Tsugawa H, et al. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS One 2012;7:e47396
   PubMed Web of Science ®Google Scholar
• Zang YS, Zhong YF, Fang Z, Li B, An J. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 2012;19:773–8
   PubMed Web of Science ®Google Scholar
• Higgs G, Slack F. The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma 2013;3:17. doi: 10.1186/2043-9113-3-17
   PubMedGoogle Scholar
• Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007;316:608–11
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Chen C, et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2009;113:4391–402
   PubMed Web of Science ®Google Scholar
• Zheng SR, Guo GL, Zhai Q, et al. Effects of miR-155 antisense oligonucleotide on breast carcinoma cell line MDA-MB-157 and implanted tumors. Asian Pac J Cancer Prev 2013;14:2361–6
   PubMed Web of Science ®Google Scholar
• Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol 2005;560:125–39
   PubMed Web of Science ®Google Scholar
• Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes: a new member of the immunoglobulin superfamily. J Immunol 1989;143:712–17
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Poe JC, Jansen PJ, et al. CD19 amplifies B lymphocyte signal regulates Src-family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000;13:47–57
   PubMed Web of Science ®Google Scholar
• Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352–5
   PubMed Web of Science ®Google Scholar
• Sato S, Steeber DA, Tedder TF. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci USA 1995;92:11558–62
   PubMed Web of Science ®Google Scholar
• Cannizzo E, Carulli G, Del Vecchio L, et al. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. Am J Clin Pathol 2012;137:377–86
   PubMed Web of Science ®Google Scholar
• Mahmoud MS, Fujii R, Ishikawa H, Kawano MM. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 1999;94:3551–8
   PubMed Web of Science ®Google Scholar
• Mateo G, Montalbán MA, Vidriales MB, et al.; PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26:2737–44
   PubMed Web of Science ®Google Scholar
• Jeong TD, Park CJ, Shim H, et al. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Korean J Hematol 2012;47:260–6
   PubMedGoogle Scholar
• Yao R, Ma YL, Liang W, et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One 2012;7:e46082
   PubMed Web of Science ®Google Scholar
• Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 2006;67:1–9
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425–30
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007;104:1604–9
   PubMed Web of Science ®Google Scholar
• Kutty RK, Nagineni CN, Samuel W, et al. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun 2010;402:390–5
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010;70:3119–27
   PubMed Web of Science ®Google Scholar
• Rai D, Kim SW, McKeller MR, et al. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010;107:3111–16
   PubMed Web of Science ®Google Scholar
• Leaman D, Chen PY, Fak J, et al. Antisense-mediated depletion reveals essential and specific functions of microRNAs in Drosophila development. Cell 2005;121:1097–108
   PubMed Web of Science ®Google Scholar
• Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34:2294–304
   PubMed Web of Science ®Google Scholar
• Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87–98
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu X, Gu J, et al. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 2010;15:215–21
   PubMed Web of Science ®Google Scholar
• Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods 2008;44:55–60
   PubMed Web of Science ®Google Scholar
• Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011;18:1104–10
   PubMed Web of Science ®Google Scholar